Optimistic Buy Rating for KalVista Pharmaceuticals Amid Promising Launch of Sebetralstat
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...
Why Pharvaris (PHVS) Is Advancing Today
Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...
KalVista initiated with an Outperform at JMP Securities
JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...
JMP reiterates Kalvista stock with $19 target, sees market growth
JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...
JMP Securities sets $19 target for Kalvista Pharmaceuticals stock
JMP Securities initiated coverage on Kalvista Pharmaceuticals Inc (NASDAQ: KALV), assigning a Market Outperform rating and setting a price target of $19.00. Currently trading at $8.77, the stock has ...
ETF Daily News3d
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Cross Above 50-Day Moving Average – Time to Sell?
The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). Receive News & Ratings for KalVista ...
pharmaphorum2d
Intellia trumpets CRISPR drug data, but shares fall
including KalVista Pharma's recently filed oral plasma kallikrein inhibitor sebetralstat. The lead investigator in the phase 2 trial, Danny Cohn of Amsterdam University Medical Center in the ...
Yahoo Finance4d
KalVista Pharmaceuticals, Inc. (KALV)
After hours: January 29 at 5:06:57 p.m. EST ...